Phase I and Phase I/II clinical trials have demonstrated that sunitinib inhibits FLT3 signalling in AML patients’ cells [154] and is well tolerated as both a monotherapy and with intensive chemotherapy [155,156]. This evidence concerns the gene FLT3 and acute myeloid leukemia.